ライフサイエンスコーパス: clinical test

1 ally advance this method to become a routine clinical test.

2 ributes to the overall cost reduction of the clinical test.

3 were retrospectively tested for HPV using a clinical test.

4 detection thresholds, different from Karius' clinical test.

5 integrated from both TCM practice and modern clinical tests.

6 res a clinical assessment often supported by clinical tests.

7 prediction model based solely on nonimaging clinical tests.

8 and exemptions from prescription charges for clinical tests.

9 e remains largely undetectable with standard clinical tests.

10 to-end solution for MPS-based experiments or clinical tests.

11 0 in most studies evaluating combinations of clinical tests.

12 e (Porcn) are candidate anticancer agents in clinical testing.

13 it convenient for patients to participate in clinical testing.

14 critical quality attributes appropriate for clinical testing.

15 re identified in research projects or during clinical testing.

16 n functions were ascertained with imaging or clinical testing.

17 , preclinical proof of concept, and possible clinical testing.

18 entially in analyzing patient samples during clinical testing.

19 ents for diarrhea were identified in routine clinical testing.

20 anufacture, as well as their preclinical and clinical testing.

21 tibody-drug conjugates are now in late-phase clinical testing.

22 genesis of cardiac arrest through systematic clinical testing.

23 esidual diagnostic specimens remaining after clinical testing.

24 nists are being carried forward into phase I clinical testing.

25 genome annotation, comparative genomics, and clinical testing.

26 arly-phase trials only to fail in late-stage clinical testing.

27 new tuberculosis vaccine candidates entering clinical testing.

28 Semaglutide is currently in phase 3 clinical testing.

29 herapies and regimens are currently in (pre-)clinical testing.

30 parental virus and merits consideration for clinical testing.

31 Some of these therapies have advanced to clinical testing.

32 but most CDK inhibitors have failed rigorous clinical testing.

33 pplements," which may not require additional clinical testing.

34 the same as vaccines entering Phase 1 human clinical testing.

35 bilization of such protein aggregates are in clinical testing.

36 strategy for SCLC treatment, which warrants clinical testing.

37 o minimize it will be important steps before clinical testing.

38 re currently undergoing preclinical or early clinical testing.

39 should be taken forward for experimental or clinical testing.

40 latory drugs that are in the early stages of clinical testing.

41 coding regions of the genome (the exome) for clinical testing.

42 man mHAs in numbers and potency adequate for clinical testing.

43 atients with CKD are available and ready for clinical testing.

44 pproved in 2006 and 2009 following extensive clinical testing.

45 sion that can be gradually incorporated into clinical testing.

46 to prevent relapse are in various phases of clinical testing.

47 ll-molecule inhibitors are reported to be in clinical testing.

48 ersion from MCI to AD compared with baseline clinical testing.

49 th and metastasis, thereby supporting future clinical testing.

50 clinical management of patients referred for clinical testing.

51 mising polymer-drug conjugate progressing to clinical testing.

52 hies, and that EpoD could be a candidate for clinical testing.

53 curation, model design, quality control, and clinical testing.

54 rensic science and as well as toxicology and clinical testing.

55 " to support prioritization of compounds for clinical testing.

56 argeted immunotherapies currently undergoing clinical testing.

57 te translation of experimental findings into clinical testing.

58 the laboratory on how to best adopt these in clinical testing.

59 i and BRD4i should be pursued in further pre-clinical testing.

60 efficient repeat (TsolR13) was selected for clinical testing.

61 inical model, establishing the rationale for clinical testing.

62 should have significant influence on future clinical testing.

63 ied viral pathogens in more samples than did clinical testing (30/90 versus 16/90; McNemar P = 0.001)

64 In clinical testing, Abs against PD-1 have resulted in psor

65 With further training and clinical testing across multiple sites, protocols, and i

66 vaccines have been developed and advanced in clinical testing, additional vaccine candidates may be n

67 to turn these biomarkers into an applicable clinical test after large scale validation.

68 At the point of care (POC), on-side clinical testing allows fast biomarkers determination ev

69 of predicting conversion to AD compared with clinical testing alone.

70 Serum samples were analyzed by routine clinical test and for metabolites by 1H-NMR spectroscopy

71 e respiratory samples obtained after routine clinical testing and 27 matched liquid cultures).

72 cific antigen combinations for high-priority clinical testing and establishes a generalizable approac

73 Although RTS,S has undergone extensive clinical testing and has progressed through phase III cl

74 decay engineering to design new formats for clinical testing and other fluorescence-based applicatio

75 cardiac arrest patients requires systematic clinical testing and regular follow-up to unmask the cau

76 Hence, there is a critical interplay between clinical testing and research leading to gene-disease as

77 mportance of assessing a temporal window for clinical testing and thereby questioning the accuracy of

78 Lung function was evaluated by conventional clinical tests and by impulse oscillometry in female lat

79 ment (miRAMM) is more sensitive than current clinical tests and can provide a solution for resolving

80 summarize evidence regarding the accuracy of clinical tests and classification algorithms compared wi

81 summarize evidence regarding the accuracy of clinical tests and classification algorithms compared wi

82 s applicability and potential attraction for clinical tests and disease diagnosis.

83 measure provides an added value to existing clinical tests and encourages the maintenance of life su

84 ltiplexing power required for differentiated clinical tests and the growing field of personalized med

85 Several bnMAbs are currently in clinical testing, and we offer perspectives on their use

86 sexual health or offer appropriate advice or clinical tests, and that older people tend to be hesitan

87 e leading dengue virus vaccine candidates in clinical testing are all based on live-virus vaccine pla

88 e current leading Zika vaccine candidates in clinical testing are based on live or killed virus platf

89 rtually all SARS-CoV-2 vaccines currently in clinical testing are stored in a refrigerated or frozen

90 nce, a large number of variants generated by clinical tests are reported as variants of unknown clini

91 evelopment is mentioned, results from recent clinical tests are summarized, and potential areas for i

92 he cell surface receptor cKit are undergoing clinical testing as a cell source for heart failure and

93 G and IC/anti-CTLA-4 should be developed for clinical testing as a potentially effective novel immuno

94 able immunostimulatory NCP promises to enter clinical testing as an immunotherapy against colorectal

95 arious stages of preclinical and early phase clinical testing as potential anticancer drugs.

96 the MDM2-p53 interaction have progressed to clinical testing as treatments for a variety of hematolo

97 arkers in saliva have distinct advantages in clinical tests, as they can be conveniently examined thr

98 anner, and the more potent bnMAbs will allow clinical testing at infusion doses that are practically

99 ents of T-tau and P-tau performed in routine clinical testing at the Clinical Neurochemistry Laborato

100 ntified 13 (22%) that were not identified by clinical testing at the source hospital.

101 This article describes the clinical tests available for distinguishing aggressive f

102 Clinical tests based on primer-initiated amplification o

103 Several other JAK2 inhibitors have entered clinical testing, but none have been approved and many h

104 rimarily related to lack of easily available clinical testing, but other factors included the presenc

105 As no current clinical test can diagnose individuals at risk of develo

106 To date, no clinical test can reliably diagnose the subtype.

107 A battery of clinical tests can allow early identification of neuroco

108 wide, and the timely selection of the right clinical tests can have a significant impact on their su

109 In situations in which clinical testing cannot be performed or when uncertainty

110 sts (Pseudo R-Square = 0.052) Ultrasound and Clinical tests combined (Pseudo R-Square = 0.147) are mo

111 in time (aPTT) and prothrombin time (PT) are clinical tests commonly used to screen for coagulation-f

112 We treated 5-minute Apgars as clinical "tests," compared against 18 known outcomes; we

113 Under typical clinical testing conditions, increased forward scatter h

114 comparator tool combined with representative clinical testing could reduce the burden for completing

115 ective tool for verification of C. difficile clinical testing criteria and safe reduction of inflated

116 ighlight the importance of using appropriate clinical testing criteria.

117 B patients, showing consistent results with clinical tests, demonstrate a successful application of

118 The Mallett Unit is a clinical test designed to detect the fixation disparity

119 Clinical testing detects a fraction of carbapenem-resist

120 Despite its prevalence, clinical testing does not yield a cell or molecular base

121 ced via screening programs where preliminary clinical tests employed in an asymptomatic well-populati

122 r locations designed to match those found in clinical testing environments.

123 It also showed that a blood-based clinical test for at-risk male infants and toddlers coul

124 difference (NPD), a well-established in vivo clinical test for cystic fibrosis, reflects transepithel

125 an test is marginal so that its utility as a clinical test for early diagnosis of IFI is questionable

126 no US Food and Drug Administration-approved clinical test for M. genitalium available in the United

127 d provide the basis for the first predictive clinical test for NEC.

128 probe-to-bone (PTB) test is a commonly used clinical test for osteomyelitis (OM), but its utility ha

129 We now validate a clinical test for urinary [TIMP-2].[IGFBP7] at a high-se

130 oriatic arthritis, and related agents are in clinical testing for a variety of inflammatory disorders

131 ardial infarction and are undergoing further clinical testing for cardiomyopathy.

132 potent CCR5 coreceptor antagonist that is in clinical testing for daily oral pre-exposure prophylaxis

133 re more likely than cardiac GCs to recommend clinical testing for family members even though testing

134 reatments that are undergoing preclinical or clinical testing for hypertension treatment.

135 As clinical testing for Mendelian causes of colorectal canc

136 A antibodies; such a therapy is currently in clinical testing for spinal cord injury.

137 I-A, is the only one to have been subject to clinical testing for the treatment of metastatic tumours

138 the recombinant CDR2 protein used in routine clinical testing for these antibodies.

139 half-life, are also important factors in the clinical testing for this virus.

140 that FISH and IGHV be performed as standard clinical tests for all patients with newly diagnosed CLL

141 rs and are the basis for a growing number of clinical tests for cancer screening and surveillance.

142 needed and suggest specific experimental and clinical tests for each major theory that might help to

143 e could inform the design of next-generation clinical tests for hidden hearing disorders.

144 ity could pave the way to the development of clinical tests for monitoring gut microbial health.

145 n the CT alone, which are ignored in current clinical tests for PI resistance, conferred PI resistanc

146 Most of the available clinical tests for prognosis of post-anoxic coma are inf

147 alogous techniques for signal enhancement in clinical tests for proteins or cells.

148 tumor-derived RNA in the blood are promising clinical tests for SI-NET.

149 colleagues report the performance of various clinical tests for the detection of mecC-harboring methi

150 irectly compared eight drugs, approved or in clinical testing, for the ability to block entry mediate

151 sed on a combination of symptoms, signs, and clinical tests, given that any one of these alone would

152 targeting this protein that are amenable for clinical testing has been challenging.

153 pigenetic biomarkers and translating them to clinical tests has been difficult due in part to limitat

154 Early prototype development and clinical testing have shown that a consumer digital came

155 Successes in randomized clinical testing have supported the growing appreciation

156 less likely to fail in the various stages of clinical testing, have fewer postapproval withdrawals, a

157 liable predictors of hepatic toxicity in non-clinical testing; however, mice are considered to be a s

158 tive tool to predict the risk of ACR, and as clinical test in translational studies that aim to impro

159 with unusual cytotoxic properties that is in clinical testing in cancer.

160 se (FAK) inhibitors are currently undergoing clinical testing in combination with anti-PD-1 immune ch

161 Phase II clinical testing in ERBB2 exon 20-mutant non-small cell

162 The results warrant further clinical testing in larger trials.

163 and generates proof-of-concept for ARGX-111 clinical testing in MET-positive oncologic malignancies.

164 he need to improve the efficiency of phase 2 clinical testing in neuro-oncology to expeditiously tran

165 ompound M8891, which is currently in phase I clinical testing in oncology patients.

166 reating metastatic TNBC and warrants further clinical testing in patients.

167 very, early drug development, and definitive clinical testing in pivotal trials.

168 stigational compound is currently in phase 1 clinical testing in subjects with hemophilia A or B.

169 to replace conventional long and costly pre-clinical testing in the new drug administration process.

170 een substantiated with their development and clinical testing in the treatment of cancer.

171 are unlikely to be exploitable for improving clinical tests in healthy populations.

172 re currently under intensive development and clinical testing) in individuals with DN and perhaps oth

173 t diagnostic assays that may be suitable for clinical testing, in field and laboratory settings.

174 Few tau-directed drugs are presently in clinical testing, in part because of the difficulty in i

175 bly in future applications of genomics-based clinical tests, in which the biological groups are by de

176 Clinical testing included visual acuity, visual fields,

177 Clinical tests included meibum expression and quality, t

178 Additional clinical tests included tear film break-up time (TFBUT),

179 scue was evaluated using non-invasive, human clinical testing, including fundus auto-fluorescence, op

180 al, a variety of anti-HIV genes have reached clinical testing, including gene-editing enzymes, protei

181 sting were pathogens not assessed by routine clinical tests, including rhinovirus/enterovirus, human

182 hysiological salt concentration, relevant to clinical testing, infectivity and, therefore, oncolytic

183 S identified all viruses detected by routine clinical testing (influenza A [n = 3], human metapneumov

184 (bsAbs) on a large scale for preclinical and clinical testing is a challenging task.

185 r clinical-grade immune cell processing, its clinical testing is feasible and warranted.

186 ever received a BRAF inhibitor; confirmatory clinical testing is ongoing.

187 g MRR based malaria diagnostics suitable for clinical testing is the fact that MRR baseline fluctuati

188 ed by rapid phenotypic and genotypic routine clinical tests is essential to improve diagnostic assays

189 However, in clinical testing, it has shown limited benefit in patien

190 erences were found in questionnaires scores, clinical tests, IVCM variables between therapy groups.

191 Interpretations are submitted by clinical testing laboratories, research laboratories, lo

192 method can be applied immediately in current clinical testing laboratories.

193 Current clinical tests lack the sensitivity needed for detecting

194 ques, and extensive bench, pre-clinical, and clinical testing, lead failure (LF) remains the Achilles

195 ion discrepancies between patient report and clinical testing may be owing to home lighting may initi

196 ed for a minority of ill persons and routine clinical tests may not identify H3N2v virus, the count o

197 daptive strategies, in addition to the usual clinical tests, may provide a better insight into the im

198 th period, including whole genome sequences; clinical tests, metabolomes, proteomes, and microbiomes

199 oss-validation, all the models incorporating clinical tests (models 1, 2, and 3) performed well with

200 auditory nerve fibers; however, there is no clinical test of this synaptopathy in humans.

201 ion and memory performance (as measured by a clinical test of verbal memory retention).

202 modulators or cysteamine, justifying further clinical testing of (R)-roscovitine or optimized derivat

203 of mutations in this disease, the results of clinical testing of 699 advanced melanoma patients using

204 Here, we demonstrated the development and clinical testing of a disposable, multiplexed sensing de

205 Clinical testing of a human IgG1 anti-CD27 Ab, varliluma

206 we demonstrate the technical development and clinical testing of a novel electronics enabled microflu

207 ility genes at once, suggesting that routine clinical testing of all incidence cases should be consid

208 th melanoma providing a strong rationale for clinical testing of alternative dosing regimens.

209 Results provide a rationale for broader clinical testing of AT1R-targeted molecular imaging.

210 to the identification, characterization, and clinical testing of ataluren, a new therapeutic with the

211 Our findings strongly support the clinical testing of combined hormone antagonist-low-leve

212 Further clinical testing of DENVax in different age groups and i

213 We initiated clinical testing of engineered T cells expressing an aff

214 Rn in human biology, including insights that clinical testing of FcRn inhibitors have provided into F

215 acute lymphoblastic leukemia (T-ALL) led to clinical testing of gamma-secretase inhibitors (GSIs) th

216 To allow for the clinical testing of human CMV (HCMV)-based vaccines we c

217 hese results provide compelling evidence for clinical testing of IMiDs alone and in combination with

218 tial as a non-human animal model for the pre-clinical testing of iNKT-stimulating glycolipids.

219 enhanced activity and to support the future clinical testing of intratumoral administration of immun

220 hat we provide should help with research and clinical testing of knee-ankle prostheses in real-world

221 In summary, our results support the clinical testing of lymphodepletion and PD-1/PD-L1 block

222 he feasibility for using challenge models in clinical testing of new disease intervention strategies.

223 Pharmaceutical research requires pre-clinical testing of new therapeutics using both in-vitro

224 design, and a mechanistic rationale for the clinical testing of nonviral miRNA mimetics.

225 with conventional screening and monotherapy clinical testing of novel agents.

226 It set the stage for clinical testing of novel therapeutic strategies, such a

227 e findings may support the rationale for the clinical testing of peripherally restricted CB1R antagon

228 nt method for high-content screening and pre-clinical testing of potential STAT3 inhibitors in live c

229 These include further development and clinical testing of predictive risk scores and assays; g

230 ation and provide a strong rationale for the clinical testing of TGF-beta signaling blockade to enhan

231 o and in vitro This study further encourages clinical testing of the conserved mosaic T-cell vaccine

232 based on laboratory hypotheses, but without clinical testing of the hypotheses to show utility for t

233 provide a strong rationale for extending the clinical testing of the novel antimyeloma agent I-BET762

234 e present work describes the development and clinical testing of the paper-based biosensor that measu

235 pathomechanisms of recessive RYR1 RM and pre-clinical testing of therapies for efficacy.

236 These results therefore support clinical testing of this noninvasive-targeted drug deliv

237 CD33-directed antitumor activity and support clinical testing of this novel therapeutic in patients w

238 Further optimization and clinical testing of this promising approach are indicate

239 regulators and provides a rational basis for clinical testing of this therapeutic approach.

240 otential of more pragmatic approaches to the clinical testing of vaccine candidates, the field has pr

241 targeting of CSC prompts a new paradigm for clinical testing of VS-5584: clinical trials designed wi

242 nventional metagenomic sequencing as well as clinical tests of infection, we find this assay accurate

243 Clinical tests of micronutrient levels from whole blood

244 een use of total B12 or holoTC as first-line clinical tests of vitamin B12 status.

245 ection of our data set with genes on cardiac clinical testing panels and the druggable genome reveals

246 D NGS panel tests, we analyzed data from all clinical tests performed at the Emory Genetics Laborator

247 Developing a clinical test predicting impending conversion to NV-ARMD

248 er of drug candidates and accelerate the pre-clinical testing process subject to animal testing upon

249 field (VF) values for children using common clinical test protocols for kinetic and static perimetry

250 stimation of CA activity in erythrocytes for clinical testing purposes.

251 ism that will have enormous applications for clinical testing purposes.

252 Clinical tests recorded at visits were used to calculate

253 view, we discuss advances in preclinical and clinical tests regarding retinoid formulations, specific

254 Clinical testing reliability was compared between expert

255 iants in genes associated with CPVT from WES clinical testing represent disease-associated biomarkers

256 he rise and fall of cases seen in SARS-CoV-2 clinical test results and local COVID-19 hospital admiss

257 Using clinical test results from hospital admitted patients we

258 Thus, deficits in specific clinical test results were directly associated with loca

259 ity and 99% specificity compared to original clinical test results, and 81% positive percent agreemen

260 nts, thus facilitating the interpretation of clinical test results.

261 p = 0.0000, 0.037) than controls but similar clinical tests results (p > 0.05).

262 All subjects underwent clinical tests (Schirmer I and break-up time), in vivo c

263 ust be thoroughly deciphered and appropriate clinical tests selected to follow disease progression an

264 ned from finger prick (Theranos) and 2 major clinical testing services that require standard venipunc

265 ere compared with three test set conditions: clinical test set reading with prior images, laboratory

266 ith at least one DNA virus detected in prior clinical testing showed a total percent agreement of mNG

267 imaging, FDG PET, and CSF data with routine clinical tests significantly increased the accuracy of p

268 Often, high-sensitivity, point-of-care (POC) clinical tests, such as HIV viral load, require large vo

269 roval paradigm comprising discrete phases of clinical testing that culminate in a large randomized su

270 as testified by the number of candidates in clinical testing that unselectively target both PARP-1 a

271 There are no available clinical tests that can accurately predict peanut allerg

272 Clinical tests that evaluate the sense of smell face two

273 e results show that, as compared to standard clinical tests, the provocative perturbations illuminate

274 elf, experimental medicine, and larger-scale clinical testing-there are specific needs for academic p

275 Their limited use in clinical testing though has resulted largely from uncert

276 -validated findings lay the foundation for a clinical test to distinguish progressive supranuclear pa

277 These results can guide development of a clinical test to reveal this previously unknown form of

278 17, but total time from the authorization of clinical testing to approval has remained at approximate

279 ROS and MAP) or biennial (ACT) cognitive and clinical testing to identify incident cases of dementia

280 There are no specific laboratory or clinical tests to 'rule in' or 'rule out' the diagnosis.

281 s a collection of the most commonly required clinical tests to assess the manifestations of pathologi

282 There are currently no clinical tests to assess the risk of recurrence in TNBC

283 iopurine S-methyltransferase are commonplace clinical tests to reduce hematologic problems associated

284 The need for decentralized clinical tests together with the concept of time and cos

285 multiple genes in a single disease-targeted clinical test using next generation sequencing.

286 en resistance in prostate cancer amenable to clinical testing using available targeted therapies.

287 positive negative controls in HP and CAP/CTM clinical testing was <0.5% over 6 to 7 months of testing

288 nce of weekly home monitoring over 6-monthly clinical testing was retained even when home monitoring

289 blish the effectiveness of the paradigm as a clinical test, we assessed if radial deformation hyperac

290 To translate this discovery into a clinical test, we developed an MHCII Immune Activation a

291 ord pathology more closely than conventional clinical tests, we explored the potential for spinal mag

292 Clinical tests were performed on 422 pregnancies with or

293 tatic uveal melanoma did not warrant further clinical testing when assessed by ORR, although minor tu

294 rmore, this SNP could help resolve equivocal clinical tests where plasma MMA values have been used to

295 ines are human topoisomerase I inhibitors in clinical testing with improved physicochemical and biolo

296 ible loss of visual function in LHON support clinical testing with mutated G11778A mitochondrial DNA

297 ate the advancement of promising projects to clinical testing with the contributions of multidiscipli

298 32765) is the most advanced BTK inhibitor in clinical testing, with ongoing phase III clinical trials

299 Residual serum from the next ordered clinical test (within 12 hrs) was retrieved, frozen, and

300 duced by the community to stimulate abundant clinical tests worldwide.